Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

March 11, 2024

https://www.globenewswire.com/news-release/2024/03/11/2843611/0/en/Monte-Rosa-Therapeutics-Announces-Initiation-of-IND-Enabling-Studies-for-MRT-8102-A-First-in-Class-NEK7-Directed-Molecular-Glue-Degrader-and-NLRP3-IL-1%CE%B2-Pathway-Inhibitor.html

MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome

MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseases

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.